Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

[Lu-177]-PNT2002

Next Previous
Drug Profile

[Lu-177]-PNT2002

Alternative Names: 177Lu-PNT2002; [Lu-177]-PSMA-I&T; PNT-2002

Latest Information Update: 19 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scintomics
  • Developer Lantheus Holdings; POINT Biopharma
  • Class Antineoplastics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Prostate cancer
  • Phase II Adenoid cystic carcinoma

Most Recent Events

  • 10 Feb 2025 Phase-II clinical trials in Adenoid cystic carcinoma (Recurrent, Metastatic disease) in USA (unspecified route) (NCT06322576)
  • 13 Jan 2025 Lantheus Medical Imaging in collaboration with POINT Biopharma suspends an expanded access trial for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) (IV) (NCT06033001)
  • 13 Sep 2024 Updated efficacy and adverse events data from a phase III SPLASH clinical trials in Prostate cancer presented at the 49th Annual Congress of the European Society for Medical Oncology (ESMO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top